Multi‐target angiogenesis inhibitor combined with PD‐1 inhibitors may benefit advanced non‐small cell lung cancer patients in late line after failure of EGFR‐TKI …

L Yu, Y Hu, J Xu, R Qiao, H Zhong… - … Journal of Cancer, 2023 - Wiley Online Library
Treatments for NSCLC patients with EGFR‐TKI resistance are limited. Given that
immunotherapy and antiangiogenic agents may have synergistic antitumor effects, we …
被引用次数：13 相关文章

Multi-target angiogenesis inhibitor combined with PD-1 inhibitors may benefit advanced non-small cell lung cancer patients in late line after failure of EGFR-TKI …

L Yu, Y Hu, J Xu, R Qiao, H Zhong, B Han… - … Journal of Cancer, 2023 - europepmc.org
Treatments for NSCLC patients with EGFR-TKI resistance are limited. Given that
immunotherapy and antiangiogenic agents may have synergistic antitumor effects, we …

Multi-target angiogenesis inhibitor combined with PD-1 inhibitors may benefit advanced non-small cell lung cancer patients in late line after failure of EGFR-TKI …

L Yu, Y Hu, J Xu, R Qiao, H Zhong… - … journal of cancer, 2023 - pubmed.ncbi.nlm.nih.gov
Treatments for NSCLC patients with EGFR-TKI resistance are limited. Given that
immunotherapy and antiangiogenic agents may have synergistic antitumor effects, we …